Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide

Lucy Y Ghoda, Ebtesam Nafie, Elizabeth Bloom-Saldana, Patrick T. Fueger, Timothy Synold, James Simpson, Piotr Swiderski, Kokilah Muthaiyah, Bin Zhang, Marcin Kortylewski, Steven Vonderfecht, Le Xuan Truong Nguyen, Jianying Zhang, Joycelynne Palmer, Guido Marcucci

Blood (2022) 140 (Supplement 1): 10673–10674.

https://doi.org/10.1182/blood-2022-171147

Published: 2022

Journal Articles

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Brian J Ball, Eytan Stein, Marjorie Robbins, Jianying Zhang, Ross L. Levine, Timothy Synold, Anthony S. Stein, Guido Marcucci, Yilun Liu, Alexey V Danilov

Blood (2022) 140 (Supplement 1): 11761–11762.

https://doi.org/10.1182/blood-2022-170820

Published: 2022

Journal Articles

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Blood (2022) 140 (Supplement 1): 1872–1874.

https://doi.org/10.1182/blood-2022-170323

Published: 2022

Journal Articles

Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo

Ralf Buettner, PhD, Le Xuan Truong Nguyen, PhD, Corey James Morales, BA, BS, Lisa S Chen, PhD, Timothy Synold, PhD, Dinh Hoa Hoang, BS, Bin Amber Zhang, PhD, Lucy Ghoda, PhD, Varsha Gandhi, PhD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Steven T. Rosen, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-143240

Published: 2020

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

NARROW

Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Email alerts

ASH Publications

American Society of Hematology

Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only